Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia.
COVID-19
T-cellular response
Th1 polarization
chronic lymphocytic leukaemia
vaccine
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
25
11
2022
received:
29
09
2022
accepted:
27
11
2022
medline:
29
3
2023
pubmed:
10
12
2022
entrez:
9
12
2022
Statut:
ppublish
Résumé
In chronic lymphocytic leukaemia (CLL) the efficacy of SARS-CoV-2 vaccination remains unclear as most studies have focused on humoral responses. Here we comprehensively examined humoral and cellular responses to vaccine in CLL patients. Seroconversion was observed in 55.2% of CLL with lower rate and antibody titres in treated patients. T-cell responses were detected in a significant fraction of patients. CD4
Identifiants
pubmed: 36484163
doi: 10.1111/bjh.18602
pmc: PMC9878216
doi:
Substances chimiques
COVID-19 Vaccines
0
Tumor Necrosis Factor-alpha
0
Antineoplastic Agents
0
Interferon-gamma
82115-62-6
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-57Informations de copyright
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134-43. https://doi.org/10.1182/blood.2020006965
Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European research initiative on CLL, and CLL campus. Leukemia. 2020;34(9):2354-63. https://doi.org/10.1038/s41375-020-0959-x
Fürstenau M, Langerbeins P, De Silva N, Fink AM, Robrecht S, von Tresckow J, et al. COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 2020;34(8):2225-9. https://doi.org/10.1038/s41375-020-0941-7
Cuneo A, Scarfò L, Reda G, Varettoni M, Quaglia FM, Marchetti M, et al. Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a campus CLL report. Blood. 2020;136(6):763-6. https://doi.org/10.1182/blood.2020006854
Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and campus CLL study. Leukemia. 2021;35(12):3444-54. https://doi.org/10.1038/s41375-021-01450-8
Cuneo A, Rigolin GM, Coscia M, Quaresmini G, Scarfò L, Mauro FR, et al. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. Hematol Oncol. 2021;39(4):570-4. https://doi.org/10.1002/hon.2899
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18(5):313-9. https://doi.org/10.1038/s41571-021-00487-z
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15. https://doi.org/10.1056/NEJMoa2034577
Tadmor T, Welslau M, Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2018;11(1):57-70. https://doi.org/10.1080/17474086.2018.1407645
Parry H, McIlroy G, Bruton R, Ali M, Stephens C, Damery S, et al. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukemia. Blood Cancer J. 2021;11(7):136. https://doi.org/10.1038/s41408-021-00528-x
Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165-73. https://doi.org/10.1182/blood.2021011568
Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34(11):3047-9. https://doi.org/10.1038/s41375-020-01030-2
Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39(8):1031-3. https://doi.org/10.1016/j.ccell.2021.07.012
Benjamini O, Rokach L, Itchaki G, Braester A, Shvidel L, Goldschmidt N, et al. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica. 2022;107(3):625-34. https://doi.org/10.3324/haematol.2021.279196
Teh JSK, Coussement J, Neoh ZCF, Spelman T, Lazarakis S, Slavin MA, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Adv. 2022;6(7):2014-34. https://doi.org/10.1182/bloodadvances.2021006333
Liebers N, Speer C, Benning L, Bruch PM, Kraemer I, Meissner J, et al. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood. 2022;139(1):142-7. https://doi.org/10.1182/blood.2021013445
Shen Y, Freeman JA, Holland J, Solterbeck A, Naidu K, Soosapilla A, et al. COVID-19 vaccine failure in chronic lymphocytic leukemia and monoclonal B-lymphocytosis; humoural and cellular immunity. Br J Haematol. 2022;197(1):41-51. https://doi.org/10.1111/bjh.18014
Mellinghoff SC, Robrecht S, Mayer L, Weskamm LM, Dahlke C, Gruell H, et al. SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. Leukemia. 2022;36(2):562-5. https://doi.org/10.1038/s41375-021-01500-1
Harrington P, Doores KJ, Radia D, O'Reilly A, Lam HPJ, Seow J, et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukemia. Br J Haematol. 2021;194(6):999-1006. https://doi.org/10.1111/bjh.17568
Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M, et al. COVID-19 infection in chronic myeloid leukemia after one year of the pandemic in Italy. A campus CML report. Br J Haematol. 2022;196(3):559-65. https://doi.org/10.1111/bjh.17890
Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745-63. https://doi.org/10.1146/annurev.immunol.22.012703.104702
Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28− and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011;134(1):17-32. https://doi.org/10.1111/j.1365-2567.2011.03470.x
Wingender G, Kronenberg M. OMIP-030: characterization of human T cell subsets via surface markers. Cytometry A. 2015;87(12):1067-9. https://doi.org/10.1002/cyto.a.22788
Puzzolo MC, Del Giudice I, Peragine N, Mariglia P, De Propris MS, Cappelli LV, et al. TH2/TH1 shift under ibrutinib treatment in chronic lymphocytic leukemia. Front Oncol. 2021;11:637186. https://doi.org/10.3389/fonc.2021.637186
Vardhana S, Baldo L, Morice WG 2nd, Wherry EJ. Understanding T cell responses to COVID-19 is essential for informing public health strategies. Sci Immunol. 2022;7(71):eabo1303. https://doi.org/10.1126/sciimmunol.abo1303
Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183(1):158-168.e14. https://doi.org/10.1016/j.cell.2020.08.017
Rijkers G, Murk JL, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al. Differences in antibody kinetics and functionality between severe and mild severe acute respiratory syndrome coronavirus 2 infections. J Infect Dis. 2020;222(8):1265-9. https://doi.org/10.1093/infdis/jiaa463
Mauro FR, Giannarelli D, Galluzzo CM, Vitale C, Visentin A, Riemma C, et al. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2021;35(3):737-46. https://doi.org/10.1038/s41375-020-0884-z
Pleyer C, Ali MA, Cohen JI, Tian X, Soto S, Ahn IE, et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137(2):185-9. https://doi.org/10.1182/blood.2020008758
Douglas AP, Trubiano JA, Barr I, Leung V, Slavin MA, Tam CS. Ibrutinib may impair serological responses to influenza vaccination. Haematologica. 2017;102(10):e397-e399. https://doi.org/10.3324/haematol.2017.164285
Bradley BT, Bryan A, Fink SL, Goecker EA, Roychoudhury P, Huang ML, et al. Anti-SARS-CoV-2 antibody levels measured by the AdviseDx SARS-CoV-2 assay are concordant with previously available serologic assays but are not fully predictive of sterilizing immunity. J Clin Microbiol. 2021;59(9):e0098921. https://doi.org/10.1128/JCM.00989-21
Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021;326(15):1533-5. https://doi.org/10.1001/jama.2021.15125
Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. https://doi.org/10.1126/science.abf4063
Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996-1012.e19. https://doi.org/10.1016/j.cell.2020.09.038
Zhou R, To KK, Wong YC, Liu L, Zhou B, Li X, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020;53(4):864-877.e5. https://doi.org/10.1016/j.immuni.2020.07.026
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861-80. https://doi.org/10.1016/j.cell.2021.01.007
Tan AT, Linster M, Tan CW, le Bert N, Chia WN, Kunasegaran K, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021;34(6):108728. https://doi.org/10.1016/j.celrep.2021.108728
Koch T, Mellinghoff SC, Shamsrizi P, Addo MM, Dahlke C. Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines (Basel). 2021;9(3):238. https://doi.org/10.3390/vaccines9030238
Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587(7833):270-4. https://doi.org/10.1038/s41586-020-2598-9
Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2(4):251-62. https://doi.org/10.1038/nri778
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-9. https://doi.org/10.1038/s41586-020-2814-7
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27(7):1280-9. https://doi.org/10.1038/s41591-021-01386-7
Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020;21(11):1336-45. https://doi.org/10.1038/s41590-020-0782-6
Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127(8):3052-64. https://doi.org/10.1172/JCI89756
Ludwig LM, Hawley KM, Banks DB, Thomas-Toth AT, Blazar BR, McNerney ME, et al. Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells. Cell Death Dis. 2021;12(11):1005. https://doi.org/10.1038/s41419-021-04285-4
Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10):615-32. https://doi.org/10.1038/s41577-020-00434-6
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612-21. https://doi.org/10.1182/blood-2012-09-457531
Blixt L, Wullimann D, Aleman S, Lundin J, Chen P, Gao Y, et al. T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial. Haematologica. 2022;107(4):1000-3. https://doi.org/10.3324/haematol.2021.280300
Li L, Muftuoglu M, Liang S, Basyal M, Lv J, Akdogan ME, et al. In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight. 2022;7(7):e156559. https://doi.org/10.1172/jci.insight.156559
McGee MC, August A, Huang W. BTK/ITK dual inhibitors: modulating immunopathology and lymphopenia for COVID-19 therapy. J Leukoc Biol. 2021;109(1):49-53. https://doi.org/10.1002/JLB.5COVR0620-306R
O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 1998;8(3):275-83. https://doi.org/10.1016/s1074-7613(00)80533-6
Vazquez MI, Catalan-Dibene J, Zlotnik A. B cells responses and cytokine production are regulated by their immune microenvironment. Cytokine. 2015;74(2):318-26. https://doi.org/10.1016/j.cyto.2015.02.007
Janice Oh HL, Ken-En Gan S, Bertoletti A, Tan YJ. Understanding the T cell immune response in SARS coronavirus infection. Emerg Microbes Infect. 2012;1(9):e23. https://doi.org/10.1038/emi.2012.26
Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85(23):12201-15. https://doi.org/10.1128/JVI.06048-11
Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012;7(4):e35421. https://doi.org/10.1371/journal.pone.0035421